

CLAIM AMENDMENTS

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) An ethanolate of azithromycin having an ethanol content of about 1.5% to about 3%.

2. (Original) The ethanolate of claim 1, having a water content of about 2% to about 4%.

3. (Original) The ethanolate of claim 2, wherein the water content is between about 2.5% and about 3.5%.

4. (Original) The ethanolate of claim 1, wherein the ethanol content is about 1.5% to about 2.5%.

5. (Original) The ethanolate of claim 4, wherein the water content is about 2% to about 4%.

6. (Original) The ethanolate of claim 5, wherein the water content is between about 1.5% and about 2.5%.

7. (Original) An ethanolate of azithromycin that is characterized by a powder x-ray diffraction pattern substantially as depicted in FIG. 2.

8. (Original) A method of making an ethanolate of azithromycin, comprising the steps of:
forming an azithromycin solution by dissolving azithromycin in ethanol;

adding water to the azithromycin solution such that crystallization of the azithromycin begins and a suspension is formed; and,
isolating the crystals of azithromycin.

9. (Original) The method of claim 8, further comprising maintaining the suspension at a temperature from about 30° C. to about 80° C. for a period of time, following the step of adding water to the azithromycin solution.

10. (Original) The method of claim 8, further comprising adding additional water to the suspension, and maintaining the suspension at a temperature from about 30° C. to about 80° C. for about 1 hour to about 18 hours, following the step of adding water to the azithromycin solution.

11. (Original) The method of claim 8, further comprising cooling the suspension to about 20° C., prior to the step of isolating the crystals of azithromycin.

12. (Original) The method of claim 8, wherein the ethanolate of azithromycin has an ethanol content of about 1.5% to about 3%.

13. (Original) The method of claim 8, wherein the ethanolate of azithromycin has a water content of about 2% to about 4%.

14. (Original) The method of claim 8, wherein the ethanolate is characterized by a powder x-ray diffraction pattern substantially as depicted in FIG. 2.

15. (Original) A pharmaceutical composition comprising a therapeutically effective amount of the ethanolate of the claim 1 and a pharmaceutically acceptable carrier.